Soetrisno Soetrisno

Soetrisno Soetrisno

Auto-generated profile, based on publicly available information

Soetrisno Soetrisno

Universitas Sebelas Maret, Surakarta, Indonesia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2024 in Journal of Turkish Society of Obstetric and Gynecology
Verified
Journal Article
Open access
FFFitriana Fitriana
Fitriana Fitriana
SSSoetrisno Soetrisno
Soetrisno Soetrisno
SSSri Sulistyowati
Sri Sulistyowati
DIDono Indarto
Dono Indarto
Evaluation of placental bed uterine in L-NAME-induced early-onset preeclampsia (EO-PE) like the rat model - Turkish Journal of Obstetrics and Gynecology

10 June 2024 in Indonesian Journal of Pharmacy
Verified
Journal Article
Open access
PDF file
SSSubandi Subandi
Subandi Subandi
SSSuroto Suroto
Suroto Suroto
BPBambang Purwanto
Bambang Purwanto
BWBrian Wasita
Brian Wasita
SSSoetrisno Soetrisno
Soetrisno Soetrisno
Objectives: Stroke and coronary disease are mainly caused by atherosclerosis. Quercetin in Moringa oleifera leaf extract may protect against oxidative stress. This study aimed to determine the role of quercetin in improving dyslipidemia and inhibiting atherosclerosis onset using laboratory and histological examinations. Methods: This experimental laboratory study used a double-blind randomized sampling technique and a pre- and post-test control group design. Experimental animals were divided into the control and treatment groups that received quercetin at a dose of 25 mg/kg body weight and a high-fat diet for 10 weeks from January to March 2023. Results: The Friedman's test of the effect of quercetin administration on malondialdehyde (MDA), intercellular adhesion molecule (ICAM), C-reactive proteins (CRP), and low-density lipoprotein (LDL) levels revealed significant differences between the pre- and post-test. The Wilcoxon signed-rank test for the effect of quercetin administration on MDA levels revealed a significant difference in MDA levels after quercetin administration. Paired sample statistics revealed an average decrease in ICAM and CRP levels and an increase in LDL levels after quercetin administration. Cramer's V value demonstrated a strong relationship between quercetin administration and the intensity of the carotid and coronary arteries. A one-way analysis of variance indicated significant differences in the average sizes of the coronary and carotid arteries after quercetin administration. Conclusion: The quercetin fraction of M. oleifera leaves has a satisfactory therapeutic effect in an atherosclerotic rat model.

1 May 2024 in Journal of Medicinal and Chemical Sciences
Verified
Other
Open access
PDF file
NWNoor Hafida Widyastuti
Noor Hafida Widyastuti
RCRisya Cilmiaty
Risya Cilmiaty
APAdi Prayitno
Adi Prayitno
BWBrian Wasita
Brian Wasita
SSSoetrisno Soetrisno
Soetrisno Soetrisno
Pulp capping treatment cures reversible pulpitis to restore regular pulses without feeling pain. Calcium hydroxide is often used for pulp capping treatment. Nanochitosan is chitosan in nanoparticle. Chitosan has antibacterial and anti-inflammatory properties and fulfills the requirements to be used as a pulp capping material and applied to the wound area. The study was done in vivo in a laboratory using a sample of the Sprague-Dawley mole Sprague Dawley. The study uses four groups: healthy rat groups, reversible pulpitis, given the Ca(OH)2, and the reversible pulpitis group, in which we are given nanochitosan. After 28 days, the BMP-2 and TGF-β1 levels were measured using ELISA. The results of One-way ANOVA test showed a significant value of <0.001 for BMP-2 level and p=0,016 for TGF-β1 level. There is a significant difference in the mean level of BMP-2 and TGF-β1 in the four groups. This study showed that pulpitis reversible rats that received pulp medicament with nanochitosan had higher levels of BMP-2 and TGF-β1 than those given calcium hydroxide.

1 September 2025
Verified
Journal Article
Open access
YHYetty Hambarsari
Yetty Hambarsari
SSSuroto Suroto
Suroto Suroto
DMDiah Kurnia Mirawati
Diah Kurnia Mirawati
SSSoetrisno Soetrisno
Soetrisno Soetrisno
PDParamasari Dirgahayu
Paramasari Dirgahayu
VWVitri Widyaningsih
Vitri Widyaningsih
Context: Alzheimer’s Disease (AD) is a neurodegenerative disorder with limited treatment options, primarily addressing symptoms without targeting underlying mechanisms. Emerging therapies involving secretomes, exosomes, and extracellular vesicles (EVs) show promise in modulating AD pathology, including amyloid-beta accumulation, tau aggregation, and neuroinflammation. Aims: To conduct a bibliometric analysis of global research on secretomes, exosomes, and EVs in AD to identify trends, key contributors, and future research directions. Methods: A bibliometric analysis was conducted using the Scopus database. A total of 988 studies were identified based on English-language and final publication-stage studies, reviews, and conference papers. The data were analyzed using Scopus tools, the bibliometrics R package (Biblioshiny), and VOSviewer to evaluate publication trends, key contributors, and keyword co-occurrence networks. Results: Research on secretomes, exosomes, and EVs in AD has grown steadily from 2003 to 2025, with a significant increase in publications since 2010. The studies span 397 sources, with an annual growth rate of 6.5% and a high average citation rate per article (65.55). Key topics included fundamental mechanisms (e.g., neuroinflammation, amyloid-beta, tauopathy), biomarker development, and therapeutic approaches. Emerging areas requiring further exploration include clinical applications (e.g., delivery systems), novel biomarkers (e.g., gut–brain axis indicators), and advanced analytical methods (e.g., machine learning, bioinformatics). Conclusions: This study reveals an expanding global interest in the role of secretomes, exosomes, and EVs in AD. It identifies significant trends and research gaps, emphasizing the need for translational efforts that bridge experimental insights and clinical applications. Future efforts should focus on translating promising findings into clinical applications while addressing underexplored topics and fostering international collaboration.

29 January 2024 in Journal of Renal Injury Prevention
Verified
Journal Article
Open access
RDRatih Tri Kusuma Dewi
Ratih Tri Kusuma Dewi
BPBambang Purwanto
Bambang Purwanto
BWBrian Wasita
Brian Wasita
VWVitri Widyaningsih
Vitri Widyaningsih
RCRisya Cilmiaty
Risya Cilmiaty
IPIndah Saigitaisna Putri
Indah Saigitaisna Putri
Introduction: Peritoneal dialysis (PD) is a recommended treatment for chronic kidney disease (CKD). Continuous exposure to dialysate solution in PD leads to peritoneal fibrosis, which is characterized by changes in morphology and function of the peritoneal membrane. Astaxanthin is considered to have potent antioxidant and anti-inflammatory properties, which has a promising anti-fibrosis effect and suppresses peritoneal thickness in peritoneal fibrosis. Objectives: This study aimed to investigate the impact of astaxanthin supplementation on histological features among PD model rats, which determined astaxanthin as a potential anti-fibrotic agent for PD. Materials and Methods: This study used a laboratory experimental study with a posttest-only control group design. Thirty-two male rats were divided randomly into four groups. There are two control groups and two treatment groups. Negative (NC), given intraperitoneal (IP) injection of sterilized aquadest, positive control (PC), given dialysate 4.25% injection IP. Treatment group 1 (T1) was given dialysate 4.25% injection IP and astaxanthin 0.216 mg supplementation for 14 days, and treatment group 2 (T2) was given dialysate 4.25% IP and astaxanthin 0.216 mg supplementation for 21 days. The peritoneum tissues were then collected and prepared for histological examination. Results: Astaxanthin supplementation prevents peritoneal fibrosis development in CKD model rats (P0.05). Conclusion: Astaxanthin could reduce fibrotic thickness in PD model rats. This study was relevant to conclude that astaxanthin has a potential antifibrotic agent for PD.

11 September 2025 in Pharmacia
Verified
Journal Article
Open access
PDF file
ANAlfi Noviyana
Alfi Noviyana
SSSoetrisno Soetrisno
Soetrisno Soetrisno
APAdi Prayitno
Adi Prayitno
RCRisya Cilmiaty
Risya Cilmiaty
ALAbdurahman Laqif
Abdurahman Laqif
PDParamasari Dirgahayu
Paramasari Dirgahayu
Introduction: Type 1 diabetes mellitus (T1DM) is associated with oxidative stress and metabolic dysfunction, contributing to impaired ovarian folliculogenesis and reproductive dysfunction. Meanwhile, magnesium plays a crucial role in improving insulin sensitivity, reducing oxidative stress, and supporting cellular functions. Objective: This study aimed to evaluate the effects of magnesium supplementation, insulin therapy, and their combination on metabolic biomarkers, oxidative stress, and ovarian folliculogenesis in streptozotocin (STZ)-induced T1DM rats. Methods: A total of 35 female Wistar rats were divided into five groups, namely P1 (control), P2 (diabetic untreated), P3 (diabetic + insulin 4 IU/200 g/day), P4 (diabetic + magnesium 300 mg/kg/day), and P5 (diabetic + insulin + magnesium). The treatments were administered for 21 days. Fasting blood glucose (FBG), serum insulin, IGF-1, HER2/neu, and malondialdehyde (MDA) levels were measured. Ovarian follicle counts and histopathological evaluations were conducted to assess folliculogenesis. Results: Magnesium (P4) and combination therapy (P5) significantly improved serum insulin levels (P4: 3.36 ± 0.46 mIU/L; P5: 4.19 ± 0.29 mIU/L; control: 4.05 ± 0.37 mIU/L), reduced MDA concentrations (P4: 0.94 ± 0.16 nmol/mL; P5: 0.97 ± 0.14 nmol/mL; control: 0.94 ± 0.30 nmol/mL), and restored IGF-1 levels (P5: 54.51 ± 4.45 ng/mL; control: 55.20 ± 9.69 ng/mL). Histopathological analysis showed significant follicular restoration in P5, with counts of primary, secondary, and Graafian follicles approaching normal levels (P5: 18.57 ± 2.37; control: 22.14 ± 1.35). Conclusion: Magnesium supplementation, particularly in combination with insulin, reduced oxidative stress, restored metabolic biomarkers, and improved ovarian folliculogenesis in T1DM. This combination therapy offers a promising approach for managing diabetes-related reproductive dysfunction.